Aclaris Therapeutics (ACRS) Free Cash Flow (2014 - 2026)

Aclaris Therapeutics' Free Cash Flow history runs 13 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 38.64% year-over-year to -$18.2 million; the TTM figure through Mar 2026 stood at -$52.2 million (down 322.78% YoY), while the FY2025 annual figure was -$47.1 million, down 133.38% from the prior year.
• Free Cash Flow was -$18.2 million for Q1 2026 at Aclaris Therapeutics, down from -$13.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $22.0 million in Q3 2024 to a low of -$26.9 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$13.7 million across 5 years, with a median of -$13.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 216.67% in 2023, then surged 189.65% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$19.7 million in 2022, then surged by 60.98% to -$7.7 million in 2023, then fell by 16.17% to -$8.9 million in 2024, then plunged by 46.17% to -$13.1 million in 2025, then tumbled by 39.01% to -$18.2 million in 2026.
• The last three Free Cash Flow figures came in at -$18.2 million (Q1 2026), -$13.1 million (Q4 2025), and -$11.0 million (Q3 2025), per Business Quant data.